Literature DB >> 30779683

Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence.

Justine Alderfer1, Amit Srivastava1, Raul Isturiz1, Cynthia Burman1, Judith Absalon2, Johannes Beeslaar3, John Perez4.   

Abstract

Invasive meningococcal disease (IMD), a rapidly progressing and potentially fatal illness, disproportionately affects adolescents and young adults. While IMD is best prevented by vaccination, vaccine uptake in these groups is low. An evidence-based understanding of the safety and effectiveness of concomitant vaccination of meningococcal vaccines, including the newer MenB protein vaccines and the more established MenACWY conjugate vaccines, with other vaccines recommended for adolescents and young adults may help maximize vaccination opportunities. We identified 21 studies assessing concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults. Although studies varied in methodology, concomitant administration generally did not affect immunogenicity of the meningococcal or coadministered vaccines. In some cases, reactogenicity increased following concomitant administration, but no definitive safety concerns were raised. In general, data suggest that meningococcal vaccines can be safely and effectively coadministered with other vaccines.

Entities:  

Keywords:  Invasive meningococcal disease; MenB-FHbp; adolescents; adults; concomitant; vaccination

Mesh:

Substances:

Year:  2019        PMID: 30779683      PMCID: PMC6773407          DOI: 10.1080/21645515.2019.1581542

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  59 in total

1.  Immunization of adolescents. Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1996-11-22

Review 2.  Establishing an Immunization Platform for 16-Year-Olds in the United States.

Authors: 
Journal:  J Adolesc Health       Date:  2017-04       Impact factor: 5.012

3.  Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.

Authors:  Michael P Broderick; Sandra Romero-Steiner; Gowrisankar Rajam; Scott E Johnson; Andrea Milton; Ellie Kim; Lisa J Choi; Jennifer M Radin; Daniel S Schmidt; George M Carlone; Nancy Messonnier; Dennis J Faix
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

4.  Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults.

Authors:  Roberto Gasparini; Michele Conversano; Gianni Bona; Giovanni Gabutti; Alessandra Anemona; Peter M Dull; Francesca Ceddia
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

5.  A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.

Authors:  Derek Muse; Shane Christensen; Prakash Bhuyan; Judith Absalon; Joseph J Eiden; Thomas R Jones; Laura J York; Kathrin U Jansen; Robert E O'Neill; Shannon L Harris; John L Perez
Journal:  Pediatr Infect Dis J       Date:  2016-06       Impact factor: 2.129

Review 6.  Effectiveness of meningococcal serogroup C vaccine programmes.

Authors:  Ray Borrow; Raquel Abad; Caroline Trotter; Fiona R M van der Klis; Julio A Vazquez
Journal:  Vaccine       Date:  2013-08-09       Impact factor: 3.641

7.  Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.

Authors:  Martin Alberer; Gerd Burchard; Tomas Jelinek; Emil Reisinger; Jiri Beran; Lucie Cerna Hlavata; Eduardo Forleo-Neto; Alemnew F Dagnew; Ashwani K Arora
Journal:  J Travel Med       Date:  2014-10-13       Impact factor: 8.490

8.  The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults.

Authors:  Mari Rose Aplasca-De Los Reyes; Efren Dimaano; Noel Macalalad; Ghassan Dbaibo; Veronique Bianco; Yaela Baine; Jacqueline Miller
Journal:  Hum Vaccin Immunother       Date:  2012-04-09       Impact factor: 3.452

9.  Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017.

Authors:  Candice L Robinson; José R Romero; Allison Kempe; Cynthia Pellegrini
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-02-10       Impact factor: 17.586

10.  Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.

Authors:  Shannon Stokley; Jenny Jeyarajah; David Yankey; Maria Cano; Julianne Gee; Jill Roark; Robinette C Curtis; Lauri Markowitz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-25       Impact factor: 17.586

View more
  3 in total

1.  Meningococcal Disease in Pediatric Age: A Focus on Epidemiology and Prevention.

Authors:  Giada Maria Di Pietro; Giulia Biffi; Massimo Luca Castellazzi; Claudia Tagliabue; Raffaella Pinzani; Samantha Bosis; Paola Giovanna Marchisio
Journal:  Int J Environ Res Public Health       Date:  2022-03-29       Impact factor: 3.390

2.  Meningococcal B vaccine antigen FHbp variants among disease-causing Neisseria meningitidis B isolates, Italy, 2014-2017.

Authors:  Anna Carannante; Cecilia Fazio; Arianna Neri; Florigio Lista; Silvia Fillo; Andrea Ciammaruconi; Paola Vacca; Paola Stefanelli
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240

3.  Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Tdap Vaccine: Randomized Phase IIIb Trial in Healthy Participants 9-60 Years of Age in the Philippines.

Authors:  Jaime Santos; May Emmeline Montellano; Rontgene Solante; Nicole Perreras; Stéphanie Meyer; Myew-Ling Toh; Céline Zocchetti; Claire Vigne; Cesar Mascareñas
Journal:  Pediatr Infect Dis J       Date:  2021-09-01       Impact factor: 3.806

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.